Lucijanić, M., Krečak, I., Sorić, E., Sabljić, A., Galušić, D., Holik, H. ... Kušec, R. (2023). Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis. Biochemia Medica, 33. (2). doi: 10.11613/BM.2023.020901
Lucijanić, Marko, et al. "Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis." Biochemia Medica, vol. 33, no. 2, 2023. https://doi.org/10.11613/BM.2023.020901
Lucijanić, Marko, Ivan Krečak, Ena Sorić, Anica Sabljić, Davor Galušić, Hrvoje Holik, Vlatka Periša, Martina Morić Perić, Ivan Zekanović and Rajko Kušec. "Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis." Biochemia Medica 33, no. 2 (2023). https://doi.org/10.11613/BM.2023.020901
Lucijanić, M., et al. (2023) 'Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis', Biochemia Medica, 33(2). doi: 10.11613/BM.2023.020901
Lucijanić M, Krečak I, Sorić E, Sabljić A, Galušić D, Holik H, and sur.. Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis. Biochemia Medica [Internet]. 2023 [cited 2024 September 30];33(2). doi: 10.11613/BM.2023.020901
M. Lucijanić, et al., "Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis", Biochemia Medica, vol. 33, no. 2, 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:721932. [Accessed: 30 September 2024]